Picture EBD Group Global Partnering Four Events One Price 650x80
Document › Details

LXRepair S.A.S.. (1/20/21). "Press Release: Stéphane Altaba Is Appointed CEO of the Start-up Company LXRepair". Paris.

Organisations Organisation LXRepair S.A.S.
  Organisation 2 Genomic Vision S.A. (Euronext Paris: GV)
Products Product SaferRad-LX®t predictive toxicity test for radiotherapy
Persons Person Altaba, Stéphane (LXRepair 202101– CEO before Genomic Vision + Nordic Pharma + Sanofi + Riken)
  Person 2 Sauvaigo, Sylvie (LXRepair 202101– CSO + Founder before CEO)

> Stéphane Altaba, with extensive experience in biotechnology companies, becomes CEO of LXRepair

> He will lead the commercial launch of SaferRad-LX®, the first predictive test on toxicity of radiotherapy treatments, and he is expected to raise Series A financing

LXRepair, a biotechnology start-up specializing in personalized medicine testing, today announced the appointment of Stéphane Altaba as Chief Executive Officer of LXRepair.

Stéphane Altaba brings over the last 25 years a strong experience in the pharmaceutical and diagnostic industry. His initial mission will be to lead the commercial launch of the first predictive test for the toxicity of radiotherapy treatments, called SaferRad-LX®, for patients suffering from breast and prostate cancer.

In parallel he will be responsible for raising a SerieA financing round, scheduled for 2021.

"I am delighted that Stéphane has agreed to join us in this essential development phase of the company. His experience in the field of diagnostics and his knowledge of the pharmaceutical industry and oncology will be very valuable to us. Stéphane also has a strong track record of success in developing companies, both through internal and external growth. This expertise will be very useful to us in our next fundraising campaign, which is expected to begin in 2021", said Sylvie Sauvaigo, President and Founder and CSO of LXRepair.

Stéphane Altaba, the new CEO of LXRepair, added: "I would like to thank Sylvie for her trust but also for the fantastic achievements since the creation of LXRepair. Our first test has proven its clinical relevance and will be available for Research Use Only (RUO) as early as this year, before its commercial launch as IVD in 2024. I am very excited we will be able to offer our technology to hundreds of thousands of patients in the near future. Radiotherapy oncologists have been waiting for such a product for years, one that will prevent patients’ unnecessary suffering and most importantly, serious side effects. The LXRepair technology is a very simple functional test that is fully in line with our vision of medicine of the future, which will be individualized, predictive and accessible to all".


An agricultural engineer by training (ENSAIA), Stéphane Altaba, 55 year-old, holds a PhD in biotechnology (INPL) and a degree from the École Supérieure de Commerce de Paris (ESCP-Europe).

From 1994 and for more than 12 years, Stéphane Altaba held various responsibilities within the Sanofi Group: from R&D to Industrial Affairs, then Business Development. The last position he held at Sanofi was Group Director of Oncology Agreements and Licensing.

During his 9 years with Nordic Pharma, he established several strategic partnerships with other pharmaceutical companies and set up a network of subsidiaries in Europe for the marketing of the company's main products.

In 2015, he joined Genomic Vision a molecular diagnostics company where he was a member of the board and Chief Operating Officer. He successfully reorganized the company around the main markets of interest, in diagnostics, bioproduction and precision medicine, which led to a significant growth in sales.


LXRepair is a Biotechnology company whose ambition is to provide all cancer patients with access to the best possible treatment.

Its first product, SaferRAD-LX®, a diagnostic test using LXRepair proprietary technology for analyzing individual's DNA repair capacity is expected to be launched as early as 2024. This assay will predict, the late severe toxicity occurring in patient undergoing radiotherapy treatment for prostate or breast cancer.

This simple, rapid and accurate blood test, is part of a series of assays that the company will launch in the coming years and that will bring about a lasting change in the approach to oncology care; it will prevent the patient’s suffering, loss of time and high costs associated with the administration of treatment that is inappropriate in terms of efficacy or toxicity.

Today more than 8 million patients are treated worldwide every year with radiotherapy. Approximately 10% of these patients develop late severe side effects that are often disabling and always leading to a degradation of their quality of life.


Sylvie Sauvaigo: +33.
Stéphane Altaba:

Media Relations:

Jean-Baptiste Mounier:

Record changed: 2021-04-27


Picture EBD Group Connector Personal Networking in Life Sciences 650x80

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Berlin Partner Bionnale 2021 Digital Event 650x80px

» top